#1 Clinical Trials Search in Europe

Jab-21822

JAB-21822, also known as glecirasib, is an investigational drug currently being studied in various clinical trials for the treatment of advanced solid tumors, particularly those harboring KRAS G12C mutations. This article provides an overview of the ongoing research on JAB-21822, its potential benefits, and its role in combating different types of cancer.

Table of Contents

What is JAB-21822?

JAB-21822, also known as glecirasib, is a new drug being developed to treat various types of cancer[1]. It belongs to a class of medications called KRAS G12C inhibitors. KRAS is a protein that, when mutated, can cause cells to grow uncontrollably, leading to cancer. The “G12C” refers to a specific mutation in the KRAS protein that this drug targets[3].

How Does JAB-21822 Work?

JAB-21822 works by specifically targeting and blocking the activity of the mutated KRAS G12C protein. By doing this, it aims to stop or slow down the growth of cancer cells that depend on this mutation to survive and multiply[1]. This targeted approach is part of a newer generation of cancer treatments that aim to be more effective and potentially have fewer side effects than traditional chemotherapy.

What Cancers Does JAB-21822 Treat?

JAB-21822 is being studied for the treatment of several types of cancer that have the KRAS G12C mutation. These include:

  • Non-small cell lung cancer (NSCLC): A common type of lung cancer[1]
  • Colorectal cancer: Cancer that starts in the colon or rectum[4]
  • Pancreatic cancer: Cancer of the pancreas, an organ behind the stomach[8]
  • Small intestine cancer: Cancer that occurs in the small intestine[4]
  • Appendiceal cancer: A rare cancer that starts in the appendix[4]

It’s important to note that JAB-21822 is specifically designed for cancers that have the KRAS G12C mutation. Doctors will need to test a patient’s cancer cells to see if they have this mutation before considering this treatment[3].

Clinical Trials and Research

JAB-21822 is currently being studied in several clinical trials to determine its effectiveness and safety. These trials are at different phases:

  • Phase 1/2 trials: These early studies are looking at the safety of the drug, how it’s processed by the body (pharmacokinetics), and early signs of effectiveness[1][3]
  • Phase 2 trials: These trials are further evaluating how well the drug works in specific types of cancer, such as pancreatic cancer[8]
  • Phase 3 trial: A larger trial comparing JAB-21822 in combination with another drug to standard treatment for non-small cell lung cancer[5]

Researchers are measuring various outcomes in these trials, including how many patients respond to the treatment (overall response rate), how long the treatment keeps working (duration of response), and how long patients live without their cancer getting worse (progression-free survival)[1][3].

Side Effects and Safety

As with all medications, JAB-21822 may cause side effects. The clinical trials are carefully monitoring patients for any adverse events (side effects). Some of the things they’re watching for include:

  • Changes in blood tests
  • Changes in vital signs (like blood pressure and heart rate)
  • Changes in heart rhythm (measured by ECG)
  • Effects on the eyes

The full range of potential side effects is still being studied. Patients in clinical trials are closely monitored for any unexpected effects[9].

Combination Therapies

Researchers are also studying JAB-21822 in combination with other cancer treatments. Some of these combinations include:

  • JAB-21822 + Cetuximab: Cetuximab is another type of targeted therapy used in some cancers. This combination is being studied in colorectal cancer and other cancers with the KRAS G12C mutation[4]
  • JAB-21822 + JAB-3312: JAB-3312 is another experimental drug that targets a different part of the cancer growth process. This combination is being studied in various advanced solid tumors with the KRAS G12C mutation[9]

These combination approaches aim to improve the effectiveness of treatment by attacking cancer cells in multiple ways[5].

Future Prospects

JAB-21822 is still in the research phase and is not yet approved for general use. However, the ongoing clinical trials are providing valuable information about its potential as a cancer treatment. If the results continue to be promising, it could become an important new option for patients with cancers that have the KRAS G12C mutation.

As research continues, we may learn more about which patients are most likely to benefit from this treatment, how to manage any side effects, and how it compares to or combines with other cancer therapies[8][9].

Aspect Details
Drug Name JAB-21822 (glecirasib)
Drug Type KRAS G12C inhibitor
Administration Oral tablet
Target Cancers Advanced solid tumors with KRAS G12C mutation, including NSCLC, colorectal cancer, pancreatic cancer
Clinical Trial Phases Phase 1, Phase 2, Phase 3
Study Types Monotherapy, Combination therapy (with other drugs like cetuximab, JAB-3312)
Primary Outcomes Safety, tolerability, pharmacokinetics, antitumor activity
Secondary Outcomes Overall response rate, duration of response, progression-free survival

FAQ

  • What is JAB-21822 and how does it work? JAB-21822, also called glecirasib, is a KRAS G12C inhibitor. It targets a specific mutation in the KRAS gene, which is common in certain types of cancer. By inhibiting this mutated protein, JAB-21822 aims to slow down or stop cancer growth.
  • What types of cancer is JAB-21822 being studied for? JAB-21822 is being investigated for various advanced solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer, pancreatic cancer, and other cancers with KRAS G12C mutations.
  • How is JAB-21822 administered to patients? JAB-21822 is typically administered orally as a tablet. The dosage and frequency may vary depending on the specific clinical trial and treatment plan.
  • What are the potential side effects of JAB-21822? As with any investigational drug, the full range of side effects is still being studied. Clinical trials are closely monitoring patients for adverse events, which may include changes in laboratory values, vital signs, and other health parameters.
  • How can I participate in a clinical trial for JAB-21822? To participate in a clinical trial for JAB-21822, you must meet specific eligibility criteria. These may include having a particular type of cancer with a KRAS G12C mutation. Speak with your oncologist about potential clinical trial opportunities and whether you might be a suitable candidate.

Ongoing Clinical Trials on Jab-21822

  • Study on JAB-21822 for Adults with Advanced Solid Tumors with KRAS G12C Mutation

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • KRAS G12C mutation: A specific change in the KRAS gene where glycine is replaced by cysteine at position 12. This mutation is found in some cancers and can drive tumor growth.
  • Solid tumor: An abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign or malignant.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Dose-limiting toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dosage or require a decrease in dosage.
  • Maximum tolerated dose (MTD): The highest dose of a drug that does not cause unacceptable side effects.
  • Recommended Phase 2 Dose (RP2D): The dose of a drug recommended for further testing in Phase 2 clinical trials, based on results from Phase 1 studies.
  • Overall response rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • RECIST: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Monotherapy: Treatment using a single drug.
  • Combination therapy: Treatment using two or more drugs or treatment methods.

References

  1. https://clinicaltrials.gov/study/NCT05009329
  2. https://clinicaltrials.gov/study/NCT05920941
  3. https://clinicaltrials.eu/trial/study-on-jab-21822-for-adults-with-advanced-solid-tumors-with-kras-g12c-mutation/
  4. https://clinicaltrials.gov/study/NCT05194995
  5. https://clinicaltrials.gov/study/NCT06416410
  6. https://clinicaltrials.gov/study/NCT06162169
  7. https://clinicaltrials.gov/study/NCT05875493
  8. https://clinicaltrials.gov/study/NCT06008288
  9. https://clinicaltrials.gov/study/NCT05288205